Trimethoprim, creatinine and creatinine-based equations

Area of Science:

• Pharmacology
• Nephrology
• Clinical Medicine

Background:

• Co-trimoxazole, a combination of trimethoprim and sulfamethoxazole (Sfx), is widely used for urinary tract and Pneumocystis jirovecii infections.
• Sulfamethoxazole can be nephrotoxic at high doses or with inadequate GFR adjustment.
• Trimethoprim inhibits tubular creatinine secretion, impacting GFR estimations.

Purpose of the Study:

• To review the distinct effects of trimethoprim and Sfx on serum creatinine and GFR.
• To assess the clinical relevance of these effects, particularly in kidney transplant recipients.

Main Methods:

• Literature review focusing on studies examining trimethoprim and Sfx effects on renal function.
• Analysis of evidence regarding serum creatinine changes and GFR estimations.
• Examination of clinical implications, including in kidney transplantation.

Main Results:

• Trimethoprim causes a reversible increase in serum creatinine independent of GFR changes.
• This leads to falsely decreased estimated GFR (eGFR) when using creatinine-based equations.
• Sulfamethoxazole's nephrotoxicity is dose-dependent and linked to GFR.
• The differential effects are crucial for interpreting renal function in patients on co-trimoxazole.

Conclusions:

• Trimethoprim's inhibition of creatinine secretion can lead to misinterpretation of kidney function.
• Careful consideration of co-trimoxazole's components is necessary for accurate GFR assessment, especially in vulnerable populations like kidney transplant patients.
• Distinguishing between drug-induced creatinine changes and actual nephrotoxicity is vital for appropriate clinical management.